Related Experiment Video
Updated: Jun 27, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Association of HLA-B5 with Clinical Expression and Severity of Behcet's Disease in Israel
I Krause1, Y Molad, A Weinberger
1Rheumatology Unit (IK, YM, AW), Department of Medicine E (IK), Department of Medicine B (YM, AW), Rabin Medical Center, Beilinson Campus. Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Abstract:
There were 55 Israeli patients with Behcet's disease (BD) included in a study conducted to determine the correlation between HLA-B5 and clinical manifestations and severity of the disease. The systemic manifestations of BD were analyzed in relation to HLA typing, and a systemic severity score for BD was calculated according to potential morbidity and mortality associated with various clinical features. Of the 55 patients, 42 (76.4%) were sephardic Jews, 2 (3.6%) were ashkenazi Jews, and 11 (20.0%) were Israeli Arabs. There were 39 (70.9%) HLA-B5 positive patients; they had a significantly higher incidence of thrombophlebitis and a lower rate of erythema nodosum. The HLA-B5-positive patients were significantly older at disease onset, and their severity score tended to be higher, although not statistically significant.The results of our study imply that HLA-B5 in Israeli patients is associated with specific clinical features, especially more vascular disease, and may be associated with a more severe course of BD. This is of general interest because American and North European patients also have less HLA-B5 and less severe disease. (J Clin Rheumatol 1999;5:137-140).
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease IV: Clinical Manifestations
Genital Herpes
Leishmaniasis